Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut Syndrome ...Middle East

PARAMUS, N.J., Aug. 2, 2021 /PRNewswire/ -- Epygenix Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to EPX-200 for the...

Read More Details
Finally We wish PressBee provided you with enough information of ( Epygenix Therapeutics Receives U.S. FDA Orphan Drug Designation for EPX-200 in Lennox-Gastaut Syndrome )

Also on site :

• Chart-Topping '90s Rocker, 59, Stuns Fans With Unexpected Side Career
• Country Legend Makes Generous Donations Across North America This Summer
• Hershey's 'Iconic' Chocolate Flavor 'Fuels' New Release